Aptose Biosciences Files 8-K with Exhibits
Ticker: APTOF · Form: 8-K · Filed: Mar 12, 2025 · CIK: 882361
Sentiment: neutral
Topics: filing, financials, exhibits
Related Tickers: APTO
TL;DR
APTO files 8-K with exhibits, check financials.
AI Summary
Aptose Biosciences Inc. filed an 8-K on March 11, 2025, reporting financial statements and exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and operates in the biological products sector.
Why It Matters
This filing provides updated financial and exhibit information for Aptose Biosciences Inc., which is crucial for investors and stakeholders to assess the company's current status and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc (company) — Former company name
- March 11, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits as of March 11, 2025.
What is the Commission File Number for Aptose Biosciences Inc.?
The Commission File Number for Aptose Biosciences Inc. is 001-32001.
When was Aptose Biosciences Inc. formerly known as Lorus Therapeutics Inc.?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. with a date of name change on September 5, 2014.
What is the Standard Industrial Classification code for Aptose Biosciences Inc.?
The Standard Industrial Classification code for Aptose Biosciences Inc. is 2836, for Biological Products (No Diagnostic Substances).
Where is Aptose Biosciences Inc. headquartered?
Aptose Biosciences Inc. is headquartered at 66 Wellington Street West, Suite 5300, TD Bank Tower, Toronto, A6, M5K 1E6.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 12, 2025 regarding Aptose Biosciences Inc. (APTOF).